	US 12,083,242 B2
	Alginate based particles as a temporary embolic agent
Sankalp Agarwal, Nagpur (IN); Masum Pandey, Nagpur (IN); and Andrew Lewis, Galway (IE)
Assigned to CrannMed Limited, Galway (IE)
Appl. No. 17/794,072
Filed by CrannMed Limited, Galway (IE)
PCT Filed Mar. 2, 2022, PCT No. PCT/IB2022/051852 § 371(c)(1), (2) Date Jul. 20, 2022, PCT Pub. No. WO2022/185235, PCT Pub. Date Sep. 9, 2022.
Claims priority of application No. 202121008937 (IN), filed on Mar. 3, 2021.
Prior Publication US 2023/0405179 A1, Dec. 21, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61L 24/08 (2006.01); A61L 24/00 (2006.01); A61L 24/04 (2006.01)

CPC A61L 24/08 (2013.01) [A61L 24/0015 (2013.01); A61L 24/043 (2013.01); A61L 2300/236 (2013.01); A61L 2300/41 (2013.01); A61L 2300/622 (2013.01); A61L 2400/04 (2013.01)]

21 Claims

1. An alginate microsphere capable of self-degradation upon rehydration, comprising:

an alginate lyase enzyme pre-treated by varying temperature, by varying pH, and/or with a metal-ion enzyme inhibitor;

alginate molecules having one or both of (i) a predetermined molecular weight, and (ii) a predetermined ratio of β-D-Mannuronic acid (M) blocks to α-L-Guluronic acid (G) blocks; and

a divalent metal-ion crosslinking the alginate molecules,

wherein the alginate microsphere is substantially free of water and/or sterilized.